Items Tagged ‘mekinist’

June 26th, 2017

FDA grants regular approval to dabrafenib and trametinib combination for metastatic NSCLC with BRAF V600E mutation

By

The U.S. Food and Drug Administration granted regular approvals to Tafinlar® (dabrafenib) and Mekinist® (trametinib) administered in combination for patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation as detected by an FDA-approved test. These are the first FDA approvals specifically for treatment of patients with BRAF V600E mutation-positive metastatic NSCLC. The […]

View full entry

Tags: dabrafenib, Lung Cancer, Lung Cancer - Non-Small Cell, mekinist, News, non-small cell lung cancer, precision cancer medicines, tafinlar, targeted therapy, trametinib


June 6th, 2017

Targeted Therapies Show Initial Effectiveness in Subset of Papillary Thyroid Cancer

By

Two immunotherapy drugs currently approved by the U.S. Food and Drug Administration (FDA) for the treatment of melanoma also show promise for treating a rare but aggressive form of papillary thyroid cancer. Up to 44 percent of papillary thyroid cancer patients have a B-raf mutation that can be specifically targeted by existing cancer drugs. The […]

View full entry

Tags: B-raf mutations, mekinist, News, papillary thyroid cancer, precision medicine, tafinlar, targeted therapy, Thyroid Cancer


July 21st, 2016

3-Year Survival Improved with Taflinar®/Mekinist® Combination in Advanced Melanoma

By

Patients with advanced melanoma who were treated with the combination consisting of Taflinar (dabrafenib) plus Mekinist (trametinib) had a significantly improved survival rate at 3 years compared to those treated with Taflinar only. These results were presented at the 2016 annual meeting of the American Society of Clinical Oncology (ASCO). Advanced melanoma refers to skin […]

View full entry

Tags: 2016, advanced, asco, BRAFV600E/K mutation, COMBI-d trial, dabrafenib, kinase inhibitors, mekinist, Melanoma, News, Stage IV Melanoma, Taflinar


July 25th, 2014

Study of Combination Therapy in Cutaneous Melanoma Stopped Early to Allow Crossover

By

An Independent Data Monitoring Committee recently recommended that a clinical study of the combination treatment Mekinist™ (trametinib) plus Tafinlar™ (dabrafenib) versus Zelboraf® (vemurafenib) for metastatic cutaneous melanoma patients be stopped early so that those receiving Zelboraf could cross over and begin taking the combination therapy instead. The committee made the recommendation after an interim analysis […]

View full entry

Tags: mekinist, Melanoma, News, Stage III Melanoma, Stage IV Melanoma, tafinlar, zelboraf